



204240" 85614001



INDIVIDUAL Stx2-
SPECIFIC Hu-mAb
BINDING PATTERNS

FIG.1

SUMMARY OF Stx2 Hu mAb ACTIVITY
AGAINST CLINICAL Stx2 AND Stx2 VARIANTS




FIG.2




FIG.3

AVERAGE SURVIVAL OF MICE GIVEN 5,10,20,35 OR 50 μ g
OF Stx2-SPECIFIC Hu-mAbs FOLLOWED 18 HOURS LATER
WITH 25ng Stx2





FIG.4


IN VITRO NEUTRALIZATION OF Stx2 AND Stx2c
(PRODUCED BY CLINICAL STEC ISOLATES)
BY Stx2-SPECIFIC Hu-mAb



5H8=anti-A+B subunit
6G3=anti-A+B subunit
2F10=anti-A subunit
3E9=anti-A subunit
5C12=anti-A subunit

FIG.5

AVERAGE DAYS OF SURVIVAL OF MICE GIVEN 30 μ g
Hu-m Ab 2F10, 3E9, 5C12, 5H8, OR 6G3 FOLLOWED 18 HOURS LATER
WITH Stx2c CONTAINING CULTURE SUPERNATANT



Stx2c PRODUCING E.coli ISOLATE (95-8061)

FIG.6